U.S. pharmaceutical big Pfizer signed a deal to buy development-stage weight problems drugmaker Metsera Inc., profitable a bidding struggle towards Novo Nordisk, the Danish drugmaker behind weight-loss therapies Ozempic and Wegovy.
Metsera, based mostly in New York, has no merchandise available on the market, however it’s creating oral and injectable therapies. That features some potential therapies that might goal profitable fields for weight problems and diabetes.
The deal comes as Pfizer is making an attempt to develop its personal stake in that market, a number of months after ending improvement of a possible capsule remedy for weight problems.
In an announcement issued Friday, Metsera stated Pfizer will purchase the corporate for as much as $86.25 per share, consisting of $65.60 per share in money and a contingent worth proper entitling holders to further funds of as much as $20.65 per share in money.
Metsera cited U.S. antitrust dangers in Novo’s bid, saying in its assertion that the board has decided Pfizer’s revised phrases characterize “the most effective transaction for shareholders, each from the attitude of worth and certainty of closing.”
The deal comes three days after Novo Nordisk raised the stakes in its push to outbid Pfizer, saying Tuesday it might provide to pay as a lot as $10 billion for Metsera. That was larger than its earlier bid of as much as $9 billion which sparked a lawsuit from Pfizer.
Pfizer had additionally altered the provide it made in September of almost $4.9 billion to offer extra cash up entrance, Metsera had stated.
New York-based Pfizer stated in an e-mail that it was proud of the phrases of the deal, and expects to shut the transaction shortly following the Metsera shareholder assembly on Nov. 13.
Novo Nordisk stated Saturday it might not enhance its provide and would depart the race to accumulate Metsera.
Novo’s proposed deal had concerned paying $62.20 in money for every Metsera share, up from its earlier bid of $56.50. The Danish drugmaker deliberate to tack on a contingent worth proper fee of $24, one other enchancment from its earlier bid, if sure improvement and regulatory milestones have been met.
